{"entity":{"id":"nct05009836","kind":"trial","name":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","aka":["SANOVO"],"tldr":"A phase 3 trial of Savolitinib in non-small-cell lung cancer and small-cell lung cancer, run by Hutchmed, active and no longer recruiting.","summary":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC is a phase 3 interventional study registered as NCT05009836 by Hutchmed, with 412 participants planned, started 2021-09-06 and due to reach its primary completion in 2028-05-30. Interventions recorded: Savolitinib, Placebo. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05009836","url":"https://clinicaltrials.gov/study/NCT05009836"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","met-altered-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["savolitinib"],"companies":["hutchmed"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05009836","phase":"3","setting":"A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC","sponsor":"Hutchmed","participation":[{"nct":"NCT05009836","source":"https://clinicaltrials.gov/study/NCT05009836","fetchedAt":"2026-10-07T16:53:32.717Z","studySha256":"bdaef2beb60c867dc1fd07a94fb23059687d8f4bda4b6fa78b45e91138a83fe9","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-22","leadSponsor":"Hutchmed","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":412,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2021-09-06","startedType":"actual","enrolled":412,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05009836/","neighbours":{"cancer":[{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/"}],"company":[{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/"}]}}